In most trials, CBD on its own did no better than a placebo for pain. So does CBD help with pain? For arthritis, fibromyalgia and sudden back pain, the best trials we found say no.
A 2024 review counted 16 randomized trials of CBD alone that measured pain, and 15 found no benefit over placebo. We grade each pain type below, the same way we grade the natural remedies for pain, each by its evidence.
CBD (cannabidiol) is a compound from the cannabis plant that doesn’t cause a high. It’s one of many cannabinoids, the compounds in cannabis that include THC, the part that does cause a high.
Many CBD products also contain some THC. So we keep trials of THC-containing medicines apart from trials of CBD alone.
- A 2024 review found that 15 of 16 randomized trials of CBD alone showed no pain benefit over a placebo.
- In a 24-week fibromyalgia trial of 200 adults, pain eased less with CBD than with a placebo.
- For nerve pain, 5 studies of CBD-dominant medicines (208 people) showed no clear benefit over a placebo.
- We found 0 trials of CBD gummies for pain.
Does CBD help with pain?
For most pain, CBD alone has not done better than a placebo in randomized trials. Trials in arthritis, fibromyalgia, sudden back pain, nerve pain and cancer pain found no clear benefit. Two tiny trials of CBD creams reported less pain, but they’re too small to rely on.
Low means the evidence is weak, small or early.
CBD for pain, graded by pain type
Grades are for CBD alone, except nerve pain, where the review grouped CBD-dominant medicines.
Showing every pain type. Pick a form to highlight the trials that tested it.
| Pain type | CBD alone: grade | Best CBD-alone evidence | THC-containing medicines | Main caveat |
|---|---|---|---|---|
| Arthritis | Moderate: no benefit in the two largest trials | Trials in 136 people with hand or psoriatic arthritis and 86 with knee arthritis (capsules) found no difference from placebo. A cream trial in 18 people with thumb arthritis reported less pain. | Not covered in the studies we read | Knee trial: liver enzyme rises were more common with CBD (15 vs 5 people), and its funder made the capsules. |
| Nerve pain | Low: no clear benefit in the review | A 2026 Cochrane review: 5 studies of CBD-dominant medicines (208 people); the review’s summary doesn’t say whether these contained any THC. A cream trial in 29 people with nerve pain in the legs reported less pain. | Low. THC and CBD mixes may help a few more people feel much improved, but the reviewers judged the gain not clinically relevant. | The review rated the evidence low to very low certainty. THC-dominant medicines may raise nervous system side effects. |
| Back pain | Moderate: no benefit for sudden low back pain | One dose of CBD by mouth, given to 100 emergency room patients on top of usual care, did no better than placebo. | Low. A maker-funded trial in 820 adults with long-term low back pain found a THC-rich extract cut pain 0.6 points more than placebo (0 to 10 scale). | CBD alone for long-term back pain wasn’t tested in the studies we read. Side effects were more common with the THC extract (83% vs 67%). |
| Fibromyalgia | Moderate: no benefit | The tablet trial in the study snapshot. | Not covered in the studies we read | One trial, at one clinic in Denmark. |
| Cancer pain | Low: no added benefit | CBD oil added nothing to specialist palliative care in one study of 144 people with advanced cancer. | Moderate: no benefit. Nabiximols (a THC and CBD mouth spray) or THC didn’t ease cancer pain that persisted despite opioids. | Only one CBD study. |
Safety: CBD can injure the liver and changes how some medicines work. See the safety section.
If arthritis is your pain, our graded options for joint pain and these knee pain exercises to try cover what else people use.
Do CBD gummies for pain actually work?
We found no trial of CBD gummies for pain. Gummies are swallowed, so the closest evidence is the trials of CBD taken by mouth in the table. None of them beat a placebo.
How much CBD a gummy delivers is unclear. A 2018 review of CBD studies in people found that no study had measured what share of swallowed CBD reaches the blood. Smoking was the only route measured that way.
Is CBD better than ibuprofen?
We found no trial comparing CBD with ibuprofen for chronic pain, so there's no evidence that CBD is better.
The only head-to-head we found was a pilot of 8 adults after tooth removal, with 2 people per group. Pain with the stronger CBD liquid looked similar to ibuprofen plus acetaminophen, but the authors called it exploratory.
In the knee arthritis trial, CBD added to acetaminophen did no better than a placebo added to acetaminophen.
We also graded turmeric's joint pain research and the research on acupuncture.
Are CBD products accurately labeled and legal?
Often not. In a lab test of 56 CBD gummy products, 70% held a CBD amount more than 10% off the label, and 39% contained THC.
Creams fared no better. Only 24% of CBD skin products with a labeled amount were within 10% of it. THC turned up in 35% of the 105 products tested.
In the US, the Food and Drug Administration has approved only one CBD product, a prescription drug for rare seizure disorders. The agency says it's illegal to add CBD to food or to sell it as a dietary supplement.
A 2025 federal law would also stop counting products with more than a tiny set amount of THC per container as hemp. As of October 28, 2026, the Congressional Research Service reported that this limit was set to start December 11, 2026, after Congress had already delayed it once, and that bills to delay it further had been introduced.
Who should avoid CBD?
In 12 placebo-controlled trials, CBD caused more liver problems, mostly in children with epilepsy. So did an FDA trial in healthy adults. CBD also changes how other medicines work.
- Warfarin: in two case reports, CBD raised warfarin's effect, needing a lower dose. Ask your doctor first.
- Seizure medicines: CBD raises clobazam's active form, and with valproate, the risk of liver enzyme rises.
- Liver disease: if moderate or severe, CBD builds up to much higher levels. Talk to your doctor first.
- Alcohol and sedating medicines: with CBD, alcohol and drugs that slow the brain, such as those for anxiety or sleep, raise drowsiness, which can cause injuries. Ask your pharmacist if your pain medicine is one.
- Transplant and heart medicines: CBD may raise levels of tacrolimus, sirolimus, everolimus and digoxin. Ask your pharmacist.
- Pregnant or breastfeeding: the FDA strongly advises against CBD, THC and marijuana in any form.
FAQ
How fast does CBD kick in for pain?
Blood levels of CBD peak within a few hours, according to a 2018 review of CBD studies in people. But a peak in the blood isn't pain relief, and most trials found no pain benefit from CBD alone.
Does CBD have side effects?
Yes. In trials, mostly of children with epilepsy, CBD caused more sleepiness, diarrhea and loss of appetite than a placebo, and some people had irritability or agitation. It can also harm the liver, which shows up on blood tests.
Can CBD make you fail a drug test?
It can. Many CBD products contain some THC. In a 2026 lab study of 60 healthy adults, CBD oil with small added amounts of THC led to positive urine drug tests in every group that got THC, and one sample in the CBD-only group was positive too. Researchers who tested CBD creams said studies are needed to learn whether creams with THC can cause a positive drug test.
The bottom line
CBD on its own hasn't beaten a placebo for most pain in trials, and we found no trial of gummies for pain. Medicines that also contain THC showed small benefits in a few trials, but that evidence is weak and says little about CBD alone.
Sources & References
- Moore, A., Straube, S., Fisher, E., & Eccleston, C. (2024). Cannabidiol (CBD) products for pain: Ineffective, expensive, and with potential harms. The Journal of Pain, 25(4), 833-842. https://doi.org/10.1016/j.jpain.2023.10.009
Evidence: Low. Narrative review counting 16 randomized trials of pharmaceutical-grade CBD with pain as an outcome; funders per Europe PMC: Medical Research Council, NIHR, Workers' Compensation Board Alberta; full text paywalled (abstract read). - Rasmussen, M. U., Christensen, R., Wæhrens, E. E., Henriksen, M., Duhn, P. H., Bliddal, H., & Amris, K. (2026). Cannabidiol versus placebo in patients with fibromyalgia: A randomised, double-blind, placebo-controlled, parallel-group, single-centre trial. Annals of the Rheumatic Diseases, 85(3), 566-574. https://doi.org/10.1016/j.ard.2025.07.008
Evidence: Moderate. Randomized placebo-controlled trial, n=200, 24 weeks, one clinic in Denmark; Danish hospital and foundation grants (Europe PMC record), no competing interests declared (abstract read). - Ateş, G., Welsch, P., Klose, P., Phillips, T., Lambers, B., Häuser, W., & Radbruch, L. (2026). Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews, (1), CD012182. https://doi.org/10.1002/14651858.CD012182.pub3
Evidence: Low. Cochrane review of 21 trials, n=2,187, 2 to 26 weeks; 5 trials (208 people) of CBD-dominant medicines; the authors rate the evidence low to very low certainty; no funding; one author co-wrote a maker-sponsored cannabis trial (abstract read). - Vela, J., Dreyer, L., Petersen, K. K., Arendt-Nielsen, L., Duch, K. S., & Kristensen, S. (2022). Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: A randomized, double-blind, placebo-controlled trial. Pain, 163(6), 1206-1214. https://doi.org/10.1097/j.pain.0000000000002466
Evidence: Moderate. Randomized placebo-controlled trial, n=136, 12 weeks; Funding: unknown after looking (full text paywalled; registry lead sponsor Aalborg University Hospital). - Pramhas, S., Thalhammer, T., Terner, S., Pickelsberger, D., Gleiss, A., Sator, S., & Kress, H. G. (2023). Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: A randomized, double-blind, placebo-controlled clinical trial. The Lancet Regional Health: Europe, 35, 100777. https://doi.org/10.1016/j.lanepe.2023.100777
Evidence: Low. Randomized placebo-controlled trial, n=86, 8 weeks; funded by Trigal Pharma, which formulated the CBD capsules (full text read). - Heineman, J. T., Forster, G. L., Stephens, K. L., Cottler, P. S., Timko, M. P., & DeGeorge, B. R., Jr. (2022). A randomized controlled trial of topical cannabidiol for the treatment of thumb basal joint arthritis. The Journal of Hand Surgery, 47(7), 611-620. https://doi.org/10.1016/j.jhsa.2022.03.002
Evidence: Low. Randomized crossover trial, n=18, 2 weeks per treatment; Funding: unknown (abstract read). - Xu, D. H., Cullen, B. D., Tang, M., & Fang, Y. (2020). The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Current Pharmaceutical Biotechnology, 21(5), 390-402. https://doi.org/10.2174/1389201020666191202111534
Evidence: Low. Randomized placebo-controlled trial, n=29, 4 weeks; Funding: unknown (abstract read). - Bebee, B., Taylor, D. M., Bourke, E., Pollack, K., Foster, L., Ching, M., & Wong, A. (2021). The CANBACK trial: A randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Medical Journal of Australia, 214(8), 370-375. https://doi.org/10.5694/mja2.51014
Evidence: Moderate. Randomized placebo-controlled trial, n=100, one dose; funders per Europe PMC: Austin Medical Research Foundation and NHMRC; full text paywalled (abstract read). - Karst, M., Meissner, W., Sator, S., Keßler, J., Schoder, V., & Häuser, W. (2025). Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: A phase 3 randomized placebo-controlled trial. Nature Medicine, 31(12), 4189-4196. https://doi.org/10.1038/s41591-025-03977-0
Evidence: Low. Randomized placebo-controlled trial of a THC-rich extract, n=820, 12-week double-blind phase; sponsored by the maker, Vertanical, which contributed to the design (full text read). - Häuser, W., Welsch, P., Radbruch, L., Fisher, E., Bell, R. F., & Moore, R. A. (2023). Cannabis-based medicines and medical cannabis for adults with cancer pain. Cochrane Database of Systematic Reviews, (6), CD014915. https://doi.org/10.1002/14651858.CD014915.pub2
Evidence: Low. Cochrane review of 14 studies: Low for the CBD oil outcome (one study, n=144, low certainty); Moderate for the nabiximols or THC outcome (5 trials, n=1,539, moderate certainty); Funding: unknown (abstract read). - Millar, S. A., Stone, N. L., Yates, A. S., & O'Sullivan, S. E. (2018). A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology, 9, 1365. https://doi.org/10.3389/fphar.2018.01365
Evidence: Low. Systematic review of small studies of how CBD moves through the body; the authors note sparse data; funded by the Biotechnology and Biological Sciences Research Council (full text read). - Abidi, A. H., Kassan, M., & Derefinko, K. (2025). Oral cannabidiol for acute post-extraction pain: A randomized pilot study. Pharmaceuticals, 18(12), 1792. https://doi.org/10.3390/ph18121792
Evidence: Low. Pilot randomized trial, n=8 (2 per group), results descriptive only; no external funding (full text read). - Johnson, E. D., Kilgore, M. W., Stafford, M., Randolph, M., Glover, M., & Babalonis, S. (2025). Cannabidiol gummy products: LC-MS/MS assessment of cannabinoid concentrations. Cannabis and Cannabinoid Research, 10(6), 710-718. https://doi.org/10.1089/can.2024.0167
Evidence: Moderate. For what it measured: a lab test of 56 gummy products from national brands sold online; Funding: unknown (abstract read). - Spindle, T. R., Sholler, D. J., Cone, E. J., Murphy, T. P., ElSohly, M., Winecker, R. E., Flegel, R. R., Bonn-Miller, M. O., & Vandrey, R. (2022). Cannabinoid content and label accuracy of hemp-derived topical products available online and at national retail stores. JAMA Network Open, 5(7), e2223019. https://doi.org/10.1001/jamanetworkopen.2022.23019
Evidence: Moderate. For what it measured: a lab test of 105 topical products; funded by SAMHSA; several authors consult for cannabis companies outside this work (full text read). - U.S. Food and Drug Administration. (2020). What you need to know (and what we're working to find out) about products containing cannabis or cannabis-derived compounds, including CBD. https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis
Evidence: Reference source. FDA consumer update (content current Mar 5, 2020), used for approval status, legal status, liver injury, sedation and side effects. - Congressional Research Service. (2026). Changes to the statutory definition of hemp and implications for agricultural policy (IF13136, updated September 28, 2026). https://www.everycrsreport.com/files/2026-09-28_IF13136_aa36fad7d69289127cbbbafef54e2aede431b2c4.html
Evidence: Reference source. Nonpartisan report to Congress (EveryCRSReport copy of the official congress.gov text, which blocks scripts), used for the 2025 change to the federal hemp definition and its start dates. - Wolinsky, D., Zamarripa, C. A., Spindle, T. R., Klausner, M., Cone, E. J., Winecker, R. E., Vikingsson, S., Flegel, R. R., Hayes, E. D., Davis, L. S., Kuntz, D., Bonn-Miller, M., Bigelow, G. E., & Vandrey, R. (2026). The acute and chronic pharmacokinetics and pharmacodynamics of oral cannabidiol with and without low doses of delta-9-tetrahydrocannabinol. Journal of Analytical Toxicology, 50(1), bkaf075. https://doi.org/10.1093/jat/bkaf075
Evidence: Moderate. For what it measured: randomized, double-blind lab study, n=60 healthy adults, urine drug tests; funded by SAMHSA; one author is employed by Charlotte's Web, a CBD maker (full text read). - Congressional Research Service. (2026). Delay in changes to hemp definition: Cannabinoids not capable of being naturally produced by the cannabis plant (Legal Sidebar LSB11496, October 28, 2026). https://www.everycrsreport.com/files/2026-10-28_LSB11496_2a4809149da4fb31c7c2e387e239a244e0e80157.html
Evidence: Reference source. Nonpartisan legal analysis for Congress, used for the current start date of the new hemp definition and pending bills. - Cortopassi, J. (2020). Warfarin dose adjustment required after cannabidiol initiation and titration. American Journal of Health-System Pharmacy, 77(22), 1846-1851. https://doi.org/10.1093/ajhp/zxaa268
Evidence: Low. Case report that also summarizes one earlier case report; Funding: unknown (abstract read). - Jazz Pharmaceuticals. (2026). EPIDIOLEX (cannabidiol) oral solution: Prescribing information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec
Evidence: Reference source. FDA-approved drug label (DailyMed version published June 15, 2026), used for drug interactions and liver enzyme warnings. - U.S. Food and Drug Administration. (2019). What you should know about using cannabis, including CBD, when pregnant or breastfeeding. https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding
Evidence: Reference source. FDA consumer update (content current Oct 16, 2019), used for the pregnancy and breastfeeding advice and the definition of CBD and THC. - Chesney, E., Oliver, D., Green, A., Sovi, S., Wilson, J., Englund, A., Freeman, T. P., & McGuire, P. (2020). Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology, 45(11), 1799-1806. https://doi.org/10.1038/s41386-020-0667-2
Evidence: Moderate. Meta-analysis of 12 double-blind placebo-controlled randomized trials (n=803) of CBD for any condition, measuring side effects; more liver test problems, sleepiness, sedation, diarrhea and loss of appetite on CBD, with the liver and sleepiness findings limited to childhood epilepsy trials. A single meta-analysis, so not Strong. Funding: Medical Research Council, NIHR and NHMRC (Europe PMC grant record). - Florian, J., Salcedo, P., Burkhart, K., Shah, A., Chekka, L. M. S., Keshishi, D., Patel, V., et al. (2025). Cannabidiol and liver enzyme level elevations in healthy adults: A randomized clinical trial. JAMA Internal Medicine, 185(9), 1070-1078. https://doi.org/10.1001/jamainternmed.2025.2366
Evidence: Moderate. Double-blind placebo-controlled trial run by US Food and Drug Administration researchers (the agency's own research), 201 healthy adults for 4 weeks; liver enzymes rose above 3 times normal in 8 people on CBD (5.6%) and none on placebo, and 7 met withdrawal criteria for possible drug-induced liver injury. One trial, short. Funding: unknown (abstract read).
How We Reviewed This Article
We rank evidence before we write. Systematic reviews, meta-analyses, and randomized controlled trials carry the most weight. Smaller trials and observational studies get cited with appropriate caveats. Consumer-perception surveys and industry-funded work get flagged as such. Every source in the References section above is tagged with its evidence strength, so you can see the grade for yourself.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your diet, exercise routine, or supplement regimen. Daily Healthy Body does not provide medical diagnoses or treatment recommendations.






